99m Tc-MIBI SPECT/CT Evaluation of a Renal Collision Tumor.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
medline:
3
7
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
Preoperative differentiation of oncocytomas from renal cell carcinoma (RCC) is often challenging. 99m Tc-MIBI imaging could play a potential role in differentiating oncocytoma from RCC, which in turn could guide surgical decision-making. We present the use of 99m Tc-MIBI SPECT/CT to characterize a renal mass in a 66-year-old man with a complex medical history, including history of bilateral oncocytomas. 99m Tc-MIBI SPECT/CT showed features suspicious of a malignant tumor, which was confirmed postnephrectomy as a chromophobe and papillary RCC collision tumor. This case supports 99m Tc-MIBI imaging for preoperative differentiation of benign versus malignant renal tumors.
Identifiants
pubmed: 37335313
doi: 10.1097/RLU.0000000000004729
pii: 00003072-202308000-00039
doi:
Substances chimiques
Technetium Tc 99m Sestamibi
971Z4W1S09
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e390-e392Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Pierorazio PM, Hyams ES, Tsai S, et al. Multiphasic enhancement patterns of small renal masses (≤4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. Urology . 2013;81:1265–1271.
Pedrosa I, Sun MR, Spencer M, et al. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics . 2008;28:985–1003.
Kim JH, Li S, Khandwala Y, et al. Association of prevalence of benign pathologic findings after partial nephrectomy with preoperative imaging patterns in the United States from 2007 to 2014. JAMA Surg . 2019;154:225–231.
Roussel E, Capitanio U, Kutikov A, et al. Novel imaging methods for renal mass characterization: a collaborative review. Eur Urol . 2022;81:476–488.
Rowe SP, Gorin MA, Gordetsky J, et al. Initial experience using 99m Tc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. Clin Nucl Med . 2015;40:309–313.
Gorin MA, Rowe SP, Baras AS, et al. Prospective evaluation of 99m Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol . 2016;69:413–416.
Rowe SP, Gorin MA, Solnes LB, et al. Correlation of 99m Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Res . 2017;7:80.
Wilson MP, Katlariwala P, Murad MH, et al. Diagnostic accuracy of 99m Tc-sestamibi SPECT/CT for detecting renal oncocytomas and other benign renal lesions: a systematic review and meta-analysis. Abdom Radiol (NY) . 2020;45:2532–2541.
Sung CT, Shetty A, Menias CO, et al. Collision and composite tumors; radiologic and pathologic correlation. Abdom Radiol (NY) . 2017;42:2909–2926.
Sistani G, Bjazevic J, Kassam Z, et al. The value of 99m Tc-sestamibi single-photon emission computed tomography-computed tomography in the evaluation and risk stratification of renal masses. Can Urol Assoc J . 2021;15:197–201.